TY - JOUR
T1 - Validation of the NSABP/NRG Oncology 8-gene trastuzumab-benefit signature in alliance/NCCTG N9831
AU - Pogue-Geile, Katherine L.
AU - Song, Nan
AU - Serie, Daniel J.
AU - Wang, Ying
AU - Gavin, Patrick G.
AU - Kim, Rim S.
AU - Tanaka, Noriko
AU - Fumagalli, Debora
AU - Taniyama, Yusuke
AU - Li, Zhuo
AU - Rastogi, Priya
AU - Swain, Sandra M.
AU - Mamounas, Eleftherios P.
AU - Geyer, Charles E.
AU - Wolmark, Norman
AU - Lucas, Peter C.
AU - Paik, Soonmyung
AU - Thompson, E. Aubrey
N1 - Publisher Copyright:
© The Author(s) 2020. Published by Oxford University Press.
PY - 2020
Y1 - 2020
N2 - Our objective was to validate the NSABP 8-gene trastuzumab-benefit signature, developed and initially validated in NRG Oncology/NSABP B-31 in Alliance/NCCTG N9831. The B-31 and N9831 trials demonstrated the benefit of adding trastuzumab to chemotherapy in the adjuvant setting for HER2þ breast cancer patients. NSABP investigators utilized gene expression profiles of N9831 patients (N ¼ 892) to blindly assign patients to large-, moderate-, or no-trastuzumab benefit groups and then NCCTG investigators assessed the degree of trastuzumab benefit using Cox models adjusted for age, nodes, estrogen receptor/progesterone receptor status, tumor size, and grade. Hazard ratios and 2-sided P values for recurrence-free survival of the predicted large- (n ¼ 387), moderate- (n ¼ 401), and no-benefit (n ¼ 104) groups, based on the 8-gene signature were 0.47 (95% CI ¼ 0.31 to 0.73, P < .001), 0.60 (95% CI ¼ 0.39 to 0.92, P ¼ .02), and 1.54 (95% CI ¼ 0.59 to 4.02, P ¼ .38), respectively (Pinteraction ¼ .02), providing validation of the 8-gene signature in an independent study.
AB - Our objective was to validate the NSABP 8-gene trastuzumab-benefit signature, developed and initially validated in NRG Oncology/NSABP B-31 in Alliance/NCCTG N9831. The B-31 and N9831 trials demonstrated the benefit of adding trastuzumab to chemotherapy in the adjuvant setting for HER2þ breast cancer patients. NSABP investigators utilized gene expression profiles of N9831 patients (N ¼ 892) to blindly assign patients to large-, moderate-, or no-trastuzumab benefit groups and then NCCTG investigators assessed the degree of trastuzumab benefit using Cox models adjusted for age, nodes, estrogen receptor/progesterone receptor status, tumor size, and grade. Hazard ratios and 2-sided P values for recurrence-free survival of the predicted large- (n ¼ 387), moderate- (n ¼ 401), and no-benefit (n ¼ 104) groups, based on the 8-gene signature were 0.47 (95% CI ¼ 0.31 to 0.73, P < .001), 0.60 (95% CI ¼ 0.39 to 0.92, P ¼ .02), and 1.54 (95% CI ¼ 0.59 to 4.02, P ¼ .38), respectively (Pinteraction ¼ .02), providing validation of the 8-gene signature in an independent study.
UR - http://www.scopus.com/inward/record.url?scp=85102071090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102071090&partnerID=8YFLogxK
U2 - 10.1093/JNCICS/PKAA058
DO - 10.1093/JNCICS/PKAA058
M3 - Article
AN - SCOPUS:85102071090
SN - 2515-5091
VL - 4
JO - JNCI Cancer Spectrum
JF - JNCI Cancer Spectrum
IS - 5
M1 - pkaa058
ER -